IRD

Opus Genetics, Inc. IRD

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,828 of 2,925

Why it scores 14Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$755.0K

Quarter to Jun 30

Net income

$-8.10M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$236.38M total
Caligan Partners LP
$24.98M0.0%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$24.78M0.0%
BIOS Capital Management, LP
$15.14M0.0%
BlackRock, Inc.
$12.81M+2009.4%
BALYASNY ASSET MANAGEMENT L.P.
$12.69M+13.6%
Nantahala Capital Management, LLC
$12.58M+82.1%
VANGUARD CAPITAL MANAGEMENT LLC
$12.16M+20.8%
Boxer Capital Management, LLC
$11.57M+25.1%
Trails Edge Capital Partners, LP
$11.28M+448.7%
MILLENNIUM MANAGEMENT LLC
$9.46M-12.5%
GREAT POINT PARTNERS LLC
$8.10M+507.4%
MARSHALL WACE, LLP
$8.00M-15.9%
ADAR1 Capital Management, LLC
$7.33M-3.5%
GOLDMAN SACHS GROUP INC
$6.28M+367.3%
Woodline Partners LP
$5.90M+6.0%
GEODE CAPITAL MANAGEMENT, LLC
$5.62M+154.1%
BOOTHBAY FUND MANAGEMENT, LLC
$4.89M0.0%
Opaleye Management Inc.
$4.62M+0.4%
SummitTX Capital, L.P.
$4.14MNew
STATE STREET CORP
$3.25M+295.2%
Bleichroeder LP
$3.03M0.0%
UBS Group AG
$2.81M+165.4%
CITADEL ADVISORS LLC
$2.74M+450.6%
MORGAN STANLEY
$1.91M+1076.3%
NORTHERN TRUST CORP
$1.82M+368.3%
See all 103 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Debt/Equity

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/IRD

Earnings Per Share

13fpro.ai/company/IRD

Loading ratio trend…

IRD key financials by period

Reported revenue, net income and operating margin by fiscal year, from Opus Genetics, Inc.'s annual filings on SEC EDGAR.

Opus Genetics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$14.2M$-49.6M—
FY 2024$11.0M$-57.5M—
FY 2023$19.0M$-10.0M-55.5%
FY 2022$39.9M$17.9M45.7%
FY 2021$589.0K$-56.7M—
FY 2019$3.0M$-6.2M-139.8%
Source: IRD filings on SEC EDGAR →

IRD insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Opus Genetics, Inc. (IRD): stock profile, AI score and financials

Opus Genetics, Inc. (IRD) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRD at 14.1/100 on a composite quality score built from its SEC filings, placing it at rank #2,828 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Opus Genetics, Inc. reports quarterly revenue of $755.0K, net income of $-8.1M. Top institutional holders of IRD by reported 13-F value include Caligan Partners, ADAGE CAPITAL PARTNERS GP, L.L.C., BIOS Capital Management, based on the most recent SEC filings. IRD trades on the Nasdaq exchange and files with the SEC under CIK 1228627. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Opus Genetics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1228627 →